DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hematologic Malignancies

Intervention: Darbepoetin alfa (Drug)

Phase: N/A

Status: Completed

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Eric Jacobsen, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

Summary

The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.

Clinical Details

Official title: A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluate the percentage of patients achieving a target hemoglobin of 11 g/dL or greater by day 100 following allogeneic stem cell transplantation.

Secondary outcome:

Evaluate the percentage of patients achieving a greater than 1 g/dL hemoglobin increase between days 30 and 100 after allogeneic stem cell transplantation

record transfusion requirements between days 30 and 100 in patients undergoing darbepoetin alfa administration following allogeneic stem cell transplantation.

Detailed description:

- Participants will receive Darbepoetin alfa through an injection under the skin, about

28-35 days after their allogeneic stem cell transplant. They will continue to receive the study drug once every three weeks for a maximum of four doses.

- Blood tests will be performed at weeks 3, 6, 9 and 12. The blood tests done at week

three will check to make sure the participant has enough iron in their system. If not, they will need to take an iron supplement. Participants will also take a folate supplement to help cell growth and reproduction.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Hematologic malignancies undergoing ablative allogeneic stem cell transplantation for

any indication

- 18 years of age or older

- Hgb of less than 10 g/dL at the time of initiation therapy

Exclusion Criteria:

- Known hypersensitivity reaction to darbepoetin alfa or any of its components

- Transfusion of packed red blood cells within 3 days of initiation of treatment with

darbepoetin alfa

- Any history of grade III or IV GVHD

- Use of any erythropoietic growth factor since transplantation

- Uncontrolled hypertension

- History of seizure

- Baseline creatinine greater than 2

- Dialysis dependence at the time of enrollment

- Hemolytic uremic syndrome

- Active GI bleeding

- Concurrent autoimmune hemolytic anemia

- Concurrent unstable angina

- History of congenital hypercoagulable state or previous venous or arterial thrombosis

- Relapsed disease prior to the initiation of study treatment

- History of renal cell carcinoma

Locations and Contacts

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Additional Information

Starting date: June 2006
Last updated: March 12, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017